The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target tumors without impacting other cells in the body.

The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.

The changes, required for safety labeling of all opioid drugs, will emphasize the risks with long-term use to combat misuse ...

Evolving trade policies and tariffs strain bio/pharmaceutical manufacturers, affecting profits and operational strategies.

EMA encourages NAMs to replace animal testing, aligning with 3Rs principles, and has published a concept paper on regulatory ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

FDA’s latest whitepaper shows how scalable quality management investments in pharma reduce costs, improve reliability, and ...

The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava ...

Re-Vana’s drug delivery technology is designed to release treatments over a 6- to 12-month period, with the goal of reducing ...

While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as ...

If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.